Exome Sequencing and the Management of Neurometabolic Disorders
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whole-exome sequencing has transformed gene discovery and diagnosis in rare diseases. Translation into disease-modifying treatments is challenging, particularly for intellectual developmental disorder. However, the exception is inborn errors of metabolism, since many of these disorders are responsive to therapy that targets pathophysiological features at the molecular or cellular level. METHODS: To uncover the genetic basis of potentially treatable inborn errors of metabolism, we combined deep clinical phenotyping (the comprehensive characterization of the discrete components of a patient's clinical and biochemical phenotype) with whole-exome sequencing analysis through a semiautomated bioinformatics pipeline in consecutively enrolled patients with intellectual developmental disorder and unexplained metabolic phenotypes. RESULTS: We performed whole-exome sequencing on samples obtained from 47 probands. Of these patients, 6 were excluded, including 1 who withdrew from the study. The remaining 41 probands had been born to predominantly nonconsanguineous parents of European descent. In 37 probands, we identified variants in 2 genes newly implicated in disease, 9 candidate genes, 22 known genes with newly identified phenotypes, and 9 genes with expected phenotypes; in most of the genes, the variants were classified as either pathogenic or probably pathogenic. Complex phenotypes of patients in five families were explained by coexisting monogenic conditions. We obtained a diagnosis in 28 of 41 probands (68%) who were evaluated. A test of a targeted intervention was performed in 18 patients (44%). CONCLUSIONS: Deep phenotyping and whole-exome sequencing in 41 probands with intellectual developmental disorder and unexplained metabolic abnormalities led to a diagnosis in 68%, the identification of 11 candidate genes newly implicated in neurometabolic disease, and a change in treatment beyond genetic counseling in 44%. (Funded by BC Children's Hospital Foundation and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“can be used to inform patient management”
From Tackling healthcare access barriers for individuals with autism from diagnosis to adulthood (2022) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
A general framework for estimating the relative pathogenicity of human genetic variants
Kircher, M., Witten, D. M., Jain, P., O'Roak, B. J., Cooper, G. M., & Shendure, J. (2014) · Nature Genetics · doi:10.1038/ng.2892 · Cited by 6,183
Cited by
Items 101–200 of 279
Tenorio, J. A., Alarcón, P., Arias, P., Dapía, I., García‐Miñáur, S., Palomares‐Bralo, M., Campistol, J., Climent, S., Valenzuela, I., Ramos, S., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0485-3 · Cited by 35
Indigenous Peoples and genomics: Starting a conversation
Morgan, J., Coe, R. R., Lesueur, R., Kenny, R., Price, R., Makela, N., & Birch, P. H. (2018) · Journal of Genetic Counseling · doi:10.1002/jgc4.1073 · Cited by 35
Santra, S., Cameron, J. M., Shyr, C., Zhang, L., Drögemöller, B. I., Ross, C. J., Wasserman, W. W., Wevers, R. A., Rodenburg, R. J., Gupte, G. L., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.03.001 · Cited by 32
Self-citationCross-Omics: Integrating Genomics with Metabolomics in Clinical Diagnostics
Kerkhofs, M. H. P. M., Haijes, H. A., Willemsen, A. M., van Gassen, K. L. I., van der Ham, M., Gerrits, J., der Velden, M. G. M. D. S., Prinsen, H. C. M. T., van Deutekom, H. W. M., van Hasselt, P. M., et al. (2020) · Metabolites · doi:10.3390/metabo10050206 · Cited by 32
“As such, NGMS may uncover abnormalities that can be linked to a genetic variant, thereby providing powerful evidence for the pathogenicity of the variant [21].”
BackgroundDe novo stop-loss variants in CLDN11 cause hypomyelinating leukodystrophy
Riedhammer, K. M., Stöckler, S., Płoski, R., Wenzel, M., Adis-Dutschmann, B., Ahting, U., Alhaddad, B., Blaschek, A., Haack, T. B., Kopajtich, R., et al. (2020) · Brain · doi:10.1093/brain/awaa410 · Cited by 30
“(*208Glnext*39), the same as in Individual 1 (Tarailo-Graovac et al., 2016).”
Self-citationSENP1 in the Retrosplenial Agranular Cortex Regulates Core Autistic-Like Symptoms in Mice
Yang, K., Shi, Y., Du, X., Wang, J., Zhang, Y., Shan, S., Yuan, Y., Wang, R., Zhou, C., Liu, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109939 · Cited by 33
Suzuki, H., Nozaki, M., Yoshihashi, H., Imagawa, K., Kajikawa, D., Yamada, M., Yamaguchi, Y., Morisada, N., Eguchi, M., Ohashi, S., et al. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.01.033 · Cited by 30
NGS Approaches in Clinical Diagnostics: From Workflow to Disease-Specific Applications
Brancato, D., Treccarichi, S., Bruno, F., Coniglio, E., Vinci, M., Saccone, S., Calì, F., & Federico, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199597 · Cited by 48
Tarailo‐Graovac, M., Drögemöller, B. I., Wasserman, W. W., Ross, C. J., van den Ouweland, A. M. W., Darín, N., Kollberg, G., van Karnebeek, C., & Blomqvist, M. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0584-6 · Cited by 28
“Using our semi-automated bioinformatics approach [11], 20 candidate genes affected by rare variants predicted to affect protein function and segregating according to Mendelian inheritance models were identified.”
BackgroundMethodSelf-citationMergnac, J.-P., Wiedemann, A., Chéry, C., Ravel, J., Namour, F., Guéant, J., Feillet, F., & Oussalah, A. (2021) · Human Genetics · doi:10.1007/s00439-021-02358-0 · Cited by 31
Gain-of-function KCNJ6 Mutation in a Severe Hyperkinetic Movement Disorder Phenotype
Horvath, G. A., Zhao, Y., Tarailo-Graovac, M., Boelman, C., Gill, H., Shyr, C., Lee, J., Blydt-Hansen, I., Drögemöller, B. I., Moreland, J., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.05.031 · Cited by 28
Self-citationOldoni, E., Saunders, G. I., Biétrix, F., García‐Bermejo, L., Niehues, A., Hoen, P. A. C. ’., Nordlund, J., Hajdúch, M., Scherer, A., Kivinen, K., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.974799 · Cited by 33
Horvath, G. A., Tarailo‐Graovac, M., Bartel, T., Race, S., Allen, M. I. V., Blydt-Hansen, I., Ross, C. J., Wasserman, W. W., Connolly, M. B., & van Karnebeek, C. (2017) · Journal of Child Neurology · doi:10.1177/0883073817740443 · Cited by 29
Self-citationCook, C. B., Armstrong, L., Boerkoel, C. F., Clarke, L. A., du Souich, C., Demos, M. K., Gibson, W. T., Gill, H., Lopez‐Rangel, E., Patel, M. S., et al. (2021) · Molecular Case Studies · doi:10.1101/mcs.a006125 · Cited by 29
“A genome analyst generated a candidate variant list using a custom bioinformatics pipeline that focused on known disease genes initially but was expanded to include all variants if the initial analysis was uninformative (Tarailo-Graovac et al. 2016; Myers et al. 2017; Sleven et al. 2017).”
MethodSelf-citationGariani, K., Nascimento, M., Superti‐Furga, A., & Tran, C. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01471-z · Cited by 32
Self-citationKawanishi, K., Saha, S., Diaz, S. L., Vaill, M., Sasmal, A., Siddiqui, S. S., Choudhury, B., Sharma, K., Chen, X., Schoenhofen, I. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci137681 · Cited by 27
“In line with glycosidically conjugated Kdn, amphibia and congenital disorders of glycosylation involving PMI, NANS, and NPL (88, 95, 96), as well as ESRD.”
Genome-wide sequencing and the clinical diagnosis of genetic disease: The CAUSES study
Elliott, A. M., Adam, S., du Souich, C., Lehman, A., Nelson, T. N., van Karnebeek, C., Alderman, E., Armstrong, L., Aubertin, G., Blood, K. A., et al. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2022.100108 · Cited by 40
“variant (SNV)/insertion or deletion (indel) calling were performed as previously described.(26,27)”
MethodSelf-citationToxic-metabolic encephalopathy in adults: Critical discussion and pragmatical diagnostic approach
Guennec, L. L., Marois, C., Demeret, S., Wijdicks, E. F. M., & Weiss, N. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2021.11.007 · Cited by 29
Diagnostic approach in adult-onset neurometabolic diseases
Fernández‐Eulate, G., Carreau, C., Benoist, J., Lamari, F., Rucheton, B., Shor, N., & Nadjar, Y. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328045 · Cited by 28
Srivastava, S., Gubbels, C. S., Dies, K. A., Fulton, A. B., Yu, T. W., & Şahin, M. (2017) · Journal of Child Neurology · doi:10.1177/0883073817711527 · Cited by 27
“In situations like this, a nonbiased NGS based approach may be advantageous and cost-effective, a conclusion reached by other studies examining the utility of whole-exome sequencing for different populations, including neurometabolic diseases.(16) Figure 3.”
Stevens, S. J. C., van der Schoot, V., Leduc, M. S., Rinne, T., Lalani, S. R., Weiss, M. M., van Hagen, J. M., Lachmeijer, A. M. A., Study, C., Stöckler‐Ipsiroglu, S., et al. (2018) · Human Mutation · doi:10.1002/humu.23541 · Cited by 26
“The bioinformatics analysis was based on a previously described pipeline (Tarailo-Graovac et al., 2016).”
Self-citationElliott, A. M., du Souich, C., Adam, S., Dragojlovic, N., van Karnebeek, C., Nelson, T. N., Lehman, A., Study, T. C., Lynd, L. D., & Friedman, J. M. (2018) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.410 · Cited by 26
“Idiopathic developmental delay/ID is the most common pediatric referral to medical genetics and is an indication for GWS (Deciphering Developmental Disorders Study, 2017; Elliott et al., 2012; Lee et al., 2014; du Souich et al., 2016; Tarailo-Graovac et al., 2016; Wright et al., 2015; Yang et al., 2014).”
BackgroundResultSelf-citationBiallelic INTS1 Mutations Cause a Rare Neurodevelopmental Disorder in Two Chinese Siblings
Zhang, X., Wang, Y., Yang, F. Y., Tang, J., Xu, X., Li, Y., Yang, X., & Wu, D. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01393-x · Cited by 24
Tarailo-Graovac, M., Wasserman, W. W., & Van Karnebeek, C. D. M. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1293527 · Cited by 23
“Blended phenotypes where multiple genetic events lead to complex clinical presentations are an appreciable cause of neurometabolic phenotypes [5,8].”
BackgroundSelf-citationRegier, D. A., Loewen, R., Chan, B., Ehman, M., Pollard, S., Friedman, J. M., Stöckler‐Ipsiroglu, S., van Karnebeek, C., Race, S., Elliott, A. M., et al. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2024.101069 · Cited by 28
Self-citationLinck, E. J. G., Richmond, P. A., Tarailo‐Graovac, M., Engelke, U. F. H., Kluijtmans, L. A. J., Coene, K. L. M., Wevers, R. A., Wasserman, W. W., van Karnebeek, C., & Mostafavi, S. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-0132-5 · Cited by 27
“More broadly, published studies applying WES coupled with variant prioritization in patients with unexplained phenotypes are successful in identifying the underlying cause in 16 to 68% of patients 6 .”
BackgroundMethodResultInfluentialSelf-citationTebani, A., Afonso, C., & Bekri, S. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0080-0 · Cited by 29
“In this regard, combining genomic and metabolic information may enhance biological inference and even clinical diagnostics (Tarailo-Graovac et al 2016; van Karnebeek et al 2016).”
BackgroundWasim, M., Khan, H. N., Ayesha, H., Goorden, S. M. I., Vaz, F. M., van Karnebeek, C., & Awan, F. R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00762 · Cited by 22
Herman, I., Jolly, A., Du, H., Dawood, M., Abdel‐Salam, G. M. H., Marafi, D., Mitani, T., Calame, D. G., Coban‐Akdemir, Z., Fatih, J. M., et al. (2021) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62565 · Cited by 19
Evaluation of the Child With Developmental Impairments
van Karnebeek, C. (2018) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000564 · Cited by 25
The utility of phenomics in diagnosis of inherited metabolic disorders
Rahman, J., & Rahman, S. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-1-30 · Cited by 21
Clinical Application of Whole Exome Sequencing to Identify Rare but Remediable Neurologic Disorders
Kim, M., Yum, M., Seo, G. H., Lee, Y., Jang, H. N., Ko, T., & Lee, B. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113724 · Cited by 19
“WES facilitates precision medicine and has changed screening and management in 41–44% of pediatric neurologic diseases, including early-onset epilepsy and neurometabolic diseases [20,21,24].”
BackgroundSharma, M., Fu, M. P., Lu, H. Y., Sharma, A., Modi, B. P., Michalski, C., Lin, S. X., Dalmann, J., Salman, A., Bel, K. L. D., et al. (2022) · Blood · doi:10.1182/blood.2022015674 · Cited by 22
Self-citationSingh, S., & Hämäläinen, R. H. (2024) · Cells · doi:10.3390/cells13020170 · Cited by 20
Exploring the feasibility of delivering standardized genomic care using ophthalmology as an example
Davison, N., Payne, K., Eden, M., McAllister, M., Roberts, S. A., Ingram, S., Black, G. C. M., & Hall, G. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.9 · Cited by 19
Tracing the evolution of sequencing into the era of genomic medicine
Mardis, E. R., & Wilson, R. K. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00884-5 · Cited by 20
“In this setting, about 25–30% of children have a finding involving the detection of a variant linked to their phenotypic description, wherein early knowledge can be life changing 124–126 .”
Comorbidities associated with genetic abnormalities in children with intellectual disability
Chen, J., Yu, W., Tsai, M., Hung, P., & Tu, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86131-3 · Cited by 25
What do parents expect from a genetic diagnosis of their child with intellectual disability?
Dikow, N., Moog, U., Karch, S., Sander, A., Kilian, S., Blank, R., & Reuner, G. (2019) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.12602 · Cited by 27
Zhang, H., Wang, Y., Qiu, Y., & Zhang, C. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.801447 · Cited by 17
Post, M. A., de Wit, I., Zijlstra, F., Engelke, U. F. H., van Rooij, A., Christodoulou, J., Tan, T. Y., Fevre, A. K. L., Jin, D., Yaplito‐Lee, J., et al. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12588 · Cited by 17
“reporting dual diagnoses causing blended phenotypes in up to 1 out of 20 rare disease cases in which whole-exome sequencing was informative.(18,19) Patient 7 was also excluded in this study due to the identification of a single heterozygous variant in MOGS.”
Backgroundvan Karnebeek, C., O’Donnell‐Luria, A., Baynam, G. S., Baudot, A., Groza, T., Jans, J. J. M., Lassmann, T., Letinturier, M. C. V., Montgomery, S. B., Robinson, P. N., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03361-0 · Cited by 22
“…diagnosis allows disease-modifying therapies to exert their effect in the crucial “neurode-velopmental time window,” potentially preventing (progression of) RD phenotypes [107] as well as somatic All in all, management changes based on ES/GS diagnoses vary from 15 to 40% in the literature [108].”
BackgroundMyopathology in the times of modern genetics
Schuelke, M., Øien, N. C., & Oldfors, A. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12374 · Cited by 18
Koko, M., Abdallah, M. O. E., Amin, M., & Ibrahim, M. E. (2018) · BMC Genomics · doi:10.1186/s12864-018-4433-3 · Cited by 17
Biallelic variants in the ciliary gene TMEM67 cause RHYNS syndrome
Undiagnosed Disease Network Italy, Brancati, F., Camerota, L., Colao, E., Vega-Warner, V., Zhao, X., Zhang, R., Bottillo, I., Castori, M., Caglioti, A., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0183-6 · Cited by 17
“More recently, Tarailo-174 Graovac et al. 10 described a young adult patient with two mutations in TMEM67 , who displayed, in addition to the MTS and cerebellar atrophy at brain imaging, mild intellectual disability, adolescent-onset dementia, vertical gaze palsy, ataxia, and progressive hepatic…”
Kuster, A., Arnoux, J., Barth, M., Lamireau, D., Houcinat, N., Goizet, C., Doray, B., Gobin, S., Schiff, M., Cano, A., et al. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0079-6 · Cited by 17
Personalized medicine for rare neurogenetic disorders: can we make it happen?
van Eeghen, A. M., Bruining, H., Wolf, N. I., Bergen, A. A. B., Houtkooper, R. H., van Haelst, M. M., & van Karnebeek, C. (2022) · PubMed Central · doi:10.1101/mcs.a006200 · Cited by 29
“This principle is illustrated by a study in which 90% of the 41 families with an unexplained neurometabolic phenotype could still be diagnosed by applying a combination of phenomics and multiomics, and in which 11 new disease genes and more than 20 new phenotypes were identified (Tarailo-Graovac et al. 2016).”
BackgroundInfluentialMau‐Them, F. T., Duffourd, Y., Vitobello, A., Bruel, A., Denommé‐Pichon, A., Nambot, S., Delanne, J., Moutton, S., Sorlin, A., Orphanomix Physician’s Group, et al. (2021) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1836 · Cited by 22
DNA Sequence Analysis in Clinical Medicine, Proceeding Cautiously
Smith, M. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00024 · Cited by 20
“DNA Sequencing in Analysis of Unexplained Rare Abnormal Metabolic Phenotypes Tarailo-Graovac et al. (2016) reported results of the combined use of deep phenotyping, metabolite and biochemical analyses and whole exome sequencing studies in patients with developmental disorders and unexplained metabolic phenotypes.”
BackgroundTarailo‐Graovac, M., Zahir, F., Zivkovic, I., Moksa, M., Selby, K. A., Sinha, S., Nislow, C., Stöckler‐Ipsiroglu, S., Sheffer, R. N., Saada, A., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.961 · Cited by 15
“The provision of genome‐ wide data from a single screen has played an important role in diagnosing rare disease patients with complex phenotypes (Posey et al., 2017; Tarailo‐Graovac et al., 2016).”
BackgroundMethodSelf-citationDual molecular diagnoses in a neurometabolic specialty clinic
Hannah‐Shmouni, F., Alshahoumi, R., Brady, L., Wu, L., Frei, J., & Tarnopolsky, M. A. (2020) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62034 · Cited by 17
Kinnear, C. J., Glanzmann, B., Banda, E., Schlechter, N., Durrheim, G. A., Neethling, A., Nel, E., Schoeman, M., Johnson, G., van Helden, P. D., et al. (2017) · BMC Medical Genetics · doi:10.1186/s12881-017-0388-5 · Cited by 16
“WES has particular value in diagnosing the cause of rare conditions with unclear phenotypes [28] or with an atypical presentation [29] as found in our index case.”
BackgroundAspartate in the Brain: A Review
Rae, C. D., Rowlands, B. D., & Balcar, V. J. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04454-3 · Cited by 21
“…in GOT2 has recently been reported in a six-year-old boy with acquired microcephaly, severe seizure disorder, spasticity, sleep disturbances, abdominal spasms, and low levels of serine in plasma and cerebrospinal fluid with some symptoms responding to oral serine and pyridoxine supplements [41].”
Salman, D. O., Mahfouz, R. A., Bitar, E. R., Samaha, J., & Karam, P. E. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1029947 · Cited by 15
“In parallel, a European study (Tarailo-Graovac et al., 2016) reported a WES diagnostic yield of 68% in 41 patients with unexplained metabolic phenotype.”
BackgroundSchork, N. J., & Nazor, K. L. (2017) · Advances in genetics · doi:10.1016/bs.adgen.2017.06.001 · Cited by 21
Diagnostic and service impact of genomic testing technologies in a neonatal intensive care unit
Tan, N. B., Tan, T. Y., Martyn, M. M., Savarirayan, R., Amor, D. J., Moody, A., White, S. M., & Stark, Z. (2019) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.14398 · Cited by 15
Adult GAMT deficiency: A literature review and report of two siblings
Modi, B. P., Khan, H. N., van der Lee, R., Wasim, M., Haaxma, C. A., Richmond, P. A., Drögemöller, B. I., Shah, S., Salomons, G. S., van der Kloet, F. M., et al. (2021) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2021.100761 · Cited by 20
“3 was analyzed using an updated version of our in-house, open-source, semi-automated bioinformatics pipeline that has been previously described [12,13].”
MethodSelf-citationGiorgio, E., Brussino, A., Biamino, E., Belligni, E. F., Bruselles, A., Ciolfi, A., Caputo, V., Pizzi, S., Calcia, A., Gregorio, E. D., et al. (2016) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2016.12.005 · Cited by 17
“Indeed, the occurrence of concomitant disorders does represent a relatively common event recognized by WES, estimating to occur in approximately 5% of the analyzed cases, and may be mistaken for new disorders or variant phenotypes of a known disorder 28-30 .”
Matthews, A., Tarailo‐Graovac, M., Price, E. M., Blydt-Hansen, I., Ghani, A., Drögemöller, B. I., Robinson, W. P., Ross, C. J., Wasserman, W. W., Siden, H. B., et al. (2017) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2017.07.015 · Cited by 17
Self-citationvan Karnebeek, C., Tarailo‐Graovac, M., Leen, R., Meinsma, R., Correard, S., Meijer, J., Prykhozhij, S. V., Pena, I. A., Ban, K., Schock, S., et al. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2024.101104 · Cited by 13
“15 Sanger sequencing was used to confirm the missense and deletion variants.”
Self-citationTan, J. K., Awuah, W. A., Ahluwalia, A., Sanker, V., Ben-Jaafar, A., Tenkorang, P. O., Aderinto, N., Mehta, A., Darko, K., Shah, M. H., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-02063-4 · Cited by 20
“Notably, successful models have been developed for conditions, such as DOPA-respon-sive dystonia, glucose transporter type 1 deficiency, and X-linked adrenoleukodystrophy [133].”
Sass, J. O., Gemperle-Britschgi, C., Tarailo‐Graovac, M., Patel, N., Walter, M., Jordanova, A., Alfadhel, M., Barić, I., Çöker, M., Damli-Huber, A., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.07.008 · Cited by 14
Self-citationWasim, M., Khan, H. N., Ayesha, H., & Awan, F. R. (2023) · Advanced Biology · doi:10.1002/adbi.202200318 · Cited by 16
Shakiba, M., & Keramatipour, M. (2018) · PubMed Central · Cited by 14
Matias, M., Wusik, K., Neilson, D., Zhang, X., Valencia, C. A., & Collins, K. (2019) · Journal of Genetic Counseling · doi:10.1002/jgc4.1054 · Cited by 13
Issa, M. Y., Chechlacz, Z., Stanley, V., George, R. D., McEvoy‐Venneri, J., Belandres, D., Elbendary, H. M., Gaber, K. R., Nabil, A., Abdel‐Hamid, M. S., et al. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0714-1 · Cited by 13
“Nevertheless, our results could help to further justify use of NGS in genetic diseases beyond clinical management of the affected proband or affected siblings, to include the potential benefit for future family planning [16].”
BackgroundMu, W., Schiess, N., Orthmann‐Murphy, J. L., & El‐Hattab, A. W. (2019) · Journal of Neurogenetics · doi:10.1080/01677063.2018.1555249 · Cited by 13
“Clinical advantages of WES are numerous, including abbreviating the path to diagnosis, informing prognosis and management, identifying medically actionable secondary findings, providing recurrence risk information, and facilitating coping and adaptation for the family (ACMG Board of Directors, 2012, 2015; Sawyer et al…”
BackgroundRare genetic diseases in India: Steps toward a nationwide mission program
Kar, A., Sundaravadivel, P., & Dalal, A. B. (2024) · Journal of Biosciences · doi:10.1007/s12038-024-00430-1 · Cited by 11
Aminoacyl‐ tRNA synthetase defects in neurological diseases
Zhang, H., & Ling, J. (2024) · IUBMB Life · doi:10.1002/iub.2924 · Cited by 13
Self-citationGerhard, G. S., Bann, D. V., Broach, J. R., & Goldenberg, D. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0011-x · Cited by 12
“Accordingly, the diagnostic rate for unselected patients undergoing exome sequencing is approximately 25%, 5 although much higher rates have recently been reported for certain conditions.(6) For many cases in which exome sequencing has been used to identify variants associated with disease, the veracity of the associa…”
Novel ACOX1 mutations in two siblings with peroxisomal acyl-CoA oxidase deficiency
Morita, A., Enokizono, T., Ohto, T., Tanaka, M., Watanabe, S., Takada, Y., Iwama, K., Mizuguchi, T., Matsumoto, N., Morita, M., et al. (2020) · Brain and Development · doi:10.1016/j.braindev.2020.10.011 · Cited by 12
Case Report: Rapid Treatment of Uridine-Responsive Epileptic Encephalopathy Caused by CAD Deficiency
Zhou, L., Deng, J., Stenton, S. L., Zhou, J., Li, H., Chen, C., Prokisch, H., & Fang, F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.608737 · Cited by 12
Heinken, A., Kouche, S. E., Guéant‐Rodriguez, R., & Guéant, J. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155738 · Cited by 14
Molecular Diagnostic Outcomes from 700 Cases
Murrell, J. R., Nesbitt, A. M. I., Baker, S. W., Pechter, K. B., Balciuniene, J., Zhao, X., Denenberg, E. H., DeChene, E. T., Wu, C., Jayaraman, P., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.12.002 · Cited by 11
Targeted versus untargeted omics — the CAFSA story
Amador, M. D. M., Colsch, B., Lamari, F., Jardel, C., Ichou, F., Rastetter, A., Sedel, F., Jourdan, F., Frainay, C., Wevers, R. A., et al. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0134-3 · Cited by 11
Self-citationTakenouchi, T., Wei, F., Suzuki, H., Uehara, T., Takahashi, T., Okazaki, Y., Kosaki, K., & Tomizawa, K. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61211 · Cited by 12
“The identification of biochemical footprints is a critical step in the diagnosis of neurometabolic disorders (Tarailo-Graovac et al., 2016).”
BackgroundMethods to Improve Molecular Diagnosis in Genomic Cold Cases in Pediatric Neurology
Kadlubowska, M. K., & Schrauwen, I. (2022) · Genes · doi:10.3390/genes13020333 · Cited by 14
Datta, A., Ferguson, A. L., Simonson, C., Zannotto, F., Michoulas, A., Roland, E. H., van Karnebeek, C., & Salvarinova, R. (2017) · Journal of Child Neurology · doi:10.1177/0883073816685508 · Cited by 10
“Gln515His was decreased to lower than 10% of wild type glutaminyltRNA synthetase.(8) The patient’s typical seizures consisted of a fencing posture, followed by right or left face and arm twitching and then generalized tonic clonic movements.”
Self-citationDragojlovic, N., Kim, E., Elliott, A. M., Study, C., Friedman, J. M., & Lynd, L. D. (2018) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12876 · Cited by 10
Self-citationMonogenic immune disorders and severe atopic disease
Biggs, C. M., Lu, H. Y., & Turvey, S. E. (2017) · Nature Genetics · doi:10.1038/ng.3925 · Cited by 10
Self-citationPotential Role of Genomic Sequencing in the Early Diagnosis of Treatable Genetic Conditions
Zahed, H., Sparks, T. N., Li, B., Alsadah, A., & Shieh, J. T. C. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.06.040 · Cited by 10
Morimoto, J., & Pietras, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-77319-4 · Cited by 8
“The frequency of, or changes to, amino acid profiles in the proteome provide insights into evolutionary mechanisms shaping genomes and their products[3– 8] and can be used in disease diagnostics[9, 10] and synthetic biology[11–13].”
BackgroundRepresenting glycophenotypes: semantic unification of glycobiology resources for disease discovery
Gourdine, J.-P. F., Brush, M., Vasilevsky, N., Shefchek, K., Köhler, S., Matentzoglu, N., Muñoz-Torres, M. C., McMurry, J. A., Zhang, X., Robinson, P. N., et al. (2019) · Database · doi:10.1093/database/baz114 · Cited by 10
“(123), similarly to the metabolomics integration in genomics (89, 124, 125).”
BackgroundA homozygous mutation in CMAS causes autosomal recessive intellectual disability in a Kazakh family
Qu, R., Sang, Q., Wang, X., Xu, Y., Chen, B., Mu, J., Zhang, Z., Li, J., He, L., & Wang, L. (2019) · Annals of Human Genetics · doi:10.1111/ahg.12349 · Cited by 10
“Meanwhile, the same group also reported NANS mutations in intellectual developmental disorders and gave suggestions for its potential management (Tarailo-Graovac et al., 2016).”
BackgroundA pediatric perspective on genomics and prevention in the twenty-first century
Chaudhari, B. P., Manickam, K., & McBride, K. L. (2019) · Pediatric Research · doi:10.1038/s41390-019-0597-z · Cited by 8
Kuilenburg, A. B. P., Tarailo‐Graovac, M., Meijer, J., Drögemöller, B. I., Vockley, J., Maurer, D., Dobritzsch, D., Ross, C. J., Wasserman, W. W., Meinsma, R., et al. (2018) · Human Mutation · doi:10.1002/humu.23538 · Cited by 10
“…according to https://varnomen.hgvs.org/. bData taken from van Kuilenburg et al., (2004). cData taken from van Kuilenburg et al., (2000). singleton-WGS (son only) and state-of-the art bioinformatics (i.e., tailored semi-automated bioinformatics approach (Tarailo-Graovac et al., 2016)) (Supp.”
Self-citationShould we respect parents’ views about which results to return from genomic sequencing?
Vears, D. F. (2021) · Human Genetics · doi:10.1007/s00439-021-02293-0 · Cited by 9
A Study on Graph Centrality Measures of Different Diseases Due to DNA Sequencing
Muhiuddin, G., Samanta, S., Aljohani, A. F., & Alkhaibari, A. M. (2023) · Mathematics · doi:10.3390/math11143166 · Cited by 12
Ahmad, R., & Naeem, M. S. (2025) · Neurogenetics · doi:10.1007/s10048-025-00819-6 · Cited by 8
“When coupled with deep clinical phenotyping, a Canadian study on neurogenetic cases with challenging metabolic phenotypes exhibited a high diagnostic yield of 68%, underlining the utility of WES for investigating neurometabolic illnesses and directing customized treatment plans [107].”
Pérez‐Torras, S., Mata-Ventosa, A., Drögemöller, B. I., Tarailo‐Graovac, M., Meijer, J., Meinsma, R., van Cruchten, A. G., Kulik, W., Viel-Oliva, A., Bidon‐Chanal, A., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.01.013 · Cited by 8
Self-citationDelanne, J., Bruel, A., Huet, F., Moutton, S., Nambot, S., Grisval, M., Houcinat, N., Kuentz, P., Sorlin, A., Callier, P., et al. (2021) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2021.100812 · Cited by 10
Fishler, K. P., Euteneuer, J. C., & Brunelli, L. (2022) · International Journal of Neonatal Screening · doi:10.3390/ijns8010022 · Cited by 10
“Additionally, patients with inborn errors of metabolism have been reported to have yields as high as 68% with WES technology [42].”
BackgroundHaskell, G., Mori, M., Powell, C. M., Amrhein, T. J., Rice, G., Bailey, L. A., Strande, N. T., Weck, K. E., Evans, J. P., Berg, J. S., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a002758 · Cited by 8
“WES has provided a molecular diagnosis in challenging cases, especially in neurometabolic disorders with nonspecific presentation (Tarailo-Graovac et al. 2016).”
BackgroundAssessment of whole-exome sequencing results in neurogenetic diseases
Balasar, Ö., & Başdemirci, M. (2023) · Journal of Human Genetics · doi:10.1038/s10038-023-01185-7 · Cited by 7
Ye, X., Roslin, N. M., Paterson, A. D., Canada, C., Lyons, C. J., Pegado, V. D., Richmond, P. A., Shyr, C., Fornés, O., Han, X., et al. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107226 · Cited by 6
Self-citationChandran, J., Bellad, A., Ramarajan, M. G., & Rangiah, K. (2021) · Analytical Science Advances · doi:10.1002/ansa.202100010 · Cited by 6
“115 Thus, it is important to note that the results of WES/WGS should be appraised carefully.”
BackgroundRivera-Munoz, E. A., Zhao, X., Rosenfeld, J. A., Luna, P. N., Shaw, C. A., Posey, J. E., & Scott, D. A. (2025) · European Journal of Human Genetics · doi:10.1038/s41431-025-01929-3 · Cited by 7
High levels of blood glutamic acid and ornithine in children with intellectual disability
Wasim, M., Khan, H. N., Ayesha, H., Tawab, A., Habib, F., Asi, M. R., Iqbal, M., & Awan, F. R. (2020) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2020.1858520 · Cited by 6
Lee, J. J. Y., Gottlieb, M. M., Lever, J., Jones, S. J. M., Blau, N., van Karnebeek, C., & Wasserman, W. W. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0125-4 · Cited by 6
“Such limitations have been recognized by the IEM community and have motivated the extensive use of biochemical tests in diagnoses (Tebani et al 2016).”
BackgroundSelf-citationPrevalence and characteristics of genetic disease in adult kidney stone formersPreprint
Anderegg, M. A., Olinger, E. G., Bargagli, M., Geraghty, R. M., Pohlmeier, L. M., Nater, A., Bruggmann, R., Sayer, J. A., Vogt, B., Schaller, A., et al. (2023) · medRxiv · doi:10.1101/2023.07.23.23292924 · Cited by 6
Ilić, N., Marić, N., Maver, A., Armengol, L., Kravljanac, R., Cirkovic, J., Krstic, J., Radivojevic, D., Cirković, S., Ostojić, S., et al. (2024) · Genes · doi:10.3390/genes15060789 · Cited by 7
“Moreover, another study reported a diagnostic success rate of 68% in cases of DD/ID and unexplained metabolic abnormalities when utilizing WES [31].”
Background
Metadata
- Authors
- Tarailo-Graovac, M., Shyr, C., Ross, C. J., Horvath, G. A., Salvarinova, R., Ye, X. C., Zhang, L.-H., Bhavsar, A. P., Lee, J. J. Y., Drögemöller, B. I., Abdelsayed, M., Alfadhel, M., Armstrong, L., Baumgartner, M. R., Burda, P., Connolly, M. B., Cameron, J., Demos, M., Dewan, T., Dionne, J., Evans, A. M., Friedman, J. M., Garber, I., Lewis, S., Ling, J., Mandal, R., Mattman, A., McKinnon, M., Michoulas, A., Metzger, D., Ogunbayo, O. A., Rakic, B., Rozmus, J., Ruben, P., Sayson, B., Santra, S., Schultz, K. R., Selby, K., Shekel, P., Sirrs, S., Skrypnyk, C., Superti-Furga, A., Turvey, S. E., Van Allen, M. I., Wishart, D., Wu, J., Wu, J., Zafeiriou, D., Kluijtmans, L., Wevers, R. A., Eydoux, P., Lehman, A. M., Vallance, H., Stockler-Ipsiroglu, S., Sinclair, G., Wasserman, W. W., & van Karnebeek, C. D.
- Affiliations
- Child and Family Research Institute (CA)
- Simon Fraser University (CA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- University Children's Hospital Zurich (CH)
- University of Toronto (CA)
- University of Edinburgh (GB)
- The University of Texas Health Science Center at Houston (US)
- University of Alberta (CA)
- Birmingham Children's Hospital (GB)
- University of British Columbia (CA)
- Arabian Gulf University (BH)
- Aristotle University of Thessaloniki (GR)
- Radboud University Medical Center (NL)
- ORCID
- Ross, Colin J.
- Horvath, Gabriella A.
- Salvarinova, Ramona
- Bhavsar, Amit P.
- Drögemöller, Britt I.
- Abdelsayed, Mena
- Alfadhel, Majid
- Armstrong, Linlea
- Baumgartner, Matthias R.
- Connolly, Mary B.
- Cameron, Jessie
- Demos, Michelle
- Dewan, Tammie
- Dionne, Janis
- Friedman, Jan M.
- Ling, Jiqiang
- McKinnon, Margaret
- Metzger, Daniel
- Ogunbayo, Oluseye A.
- Rozmus, Jacob
- Ruben, Peter
- Santra, Saikat
- Schultz, Kirk R.
- Selby, Kathryn
- Sirrs, Sandra
- Skrypnyk, Cristina
- Turvey, Stuart E.
- Wishart, David
- Wu, Jiang
- Wu, John
- Zafeiriou, Dimitrios
- Kluijtmans, Leo
- Wevers, Ron A.
- Lehman, Anna M.
- Vallance, Hilary
- Sinclair, Graham
- Wasserman, Wyeth W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-09
- Volume
- 374
- Issue
- 23
- Pages
- 2246-2255
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4983272
- OpenAlex
- W2405784650
- Cited by
- 281
- References
- 83
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 19 · 2023: 17 · 2022: 19 · 2021: 25 · 2020: 35 · 2019: 37 · 2018: 44 · 2017: 44 · 2016: 21
- FWCI
- 48.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- Summit (Simon Fraser University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- IRIS (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Genome Canada (ABC4DE)
- Children's Hospital Foundation
- BC Children's Hospital
- Michael Smith Health Research BC
- Genome British Columbia (00032, ABC4DE, SOF195, 301221)
- British Heart Foundation (RG/12/14/29885, 29885)
- University of British Columbia
- Fondation Leenaards
- Canadian Institutes of Health Research (#301221)
- National Institute of General Medical Sciences (GM115431, R01GM115431)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- exome sequencing, neurometabolic disorders, inborn errors of metabolism, intellectual disability, genetic diagnosis, candidate genes, targeted interventions, disease-modifying therapy, genetic counseling
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Female, Genetic Testing, Genotype, Humans, Infant, Male, Intellectual Disability, Metabolism, Inborn Errors, Phenotype, Sequence Analysis, DNA, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.